ClinicalTrials.gg
CompletedNCT01596725Updated Feb 6, 2014

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2

A Phase 1 interventional study of Monovalent Avian Influenza VLP (H5N1) and Monovalent Avian Influenza VLP (H5N1) in Influenza (Pandemic), sponsored by Novavax. Completed at 5 sites in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-02-06.

Sponsored by Novavax · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
333
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Influenza, Human by Novavax — none open to participants now, none under way, none of them phase 3. Influenza, Human · Novavax.

Enrollment
10th of 18
333 · median 367
Started
2012
with 2 others
Phase 1
3 of 18
none open now
Registered
9th of 18
by date

Among the 18 studies in Influenza, Human by Novavax, this one is the 10th largest by enrollment, is one of 3 that started in 2012, is one of 3 in phase 1, and was the 9th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

None of the 18 studies in Influenza, Human by Novavax is open now. The open studies under Influenza, Human, anywhere →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies in Influenza, Human by Novavax as a file.
02

Study summary

The purpose of this study is to evaluate the immunogenicity and safety profile of the Avian flu vaccine with and without adjuvant 2 in healthy, young adults. The study is divided down into Parts A1, A2 and B. Groups within each Part will receive two doses of the assigned test article on Study Days 0 and 21. There will be a Safety Monitoring Committee assessment following Day 7 for each part, prior to allowing vaccination of subjects in subsequent Parts of the study.

03

Conditions studied

  • Influenza (Pandemic)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult male or female, ≥18 and ≤49 years of age,
  2. Willing and able to give prior to study enrollment,
  3. Able to comply with study requirements, and
  4. All women must have a negative urine pregnancy test prior to each vaccination. Women will be advised through the Informed Consent process to avoid becoming pregnant over the duration of the study, and must assert that they will employ an effective form of for the duration of the study. Acceptable forms of birth control are: credible history of abstinence from heterosexual activity or prior surgical sterilization, hormonal contraceptives (oral, injectable, implant, patch, ring), double-barrier contraceptives (condom or diaphragm, with spermicide), and intrauterine device (IUD).

Exclusion criteria

Exclusion Criteria:

  1. Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care. Asymptomatic conditions (e.g., hypertension, dyslipidemia) that are being managed medically and that are not associated with evidence of end-organ damage are not exclusionary provided they are clinically stable (defined as no unscheduled medical interventions or change in medications for cause within 3 months).
  2. Any history of jaundice, or of hepatic injury due to drug (prescription, OTC, or illicit) or alcohol use or viral hepatitis; or the presence of surface antigen or antibody at screening.
  3. Any grade 1 or higher (as based on the Toxicity Grading Scale [TGS]) abnormality in serum glutamic-pyruvic transaminase/ (SGPT/ALT), serum glutamic-oxaloacetic transaminase/aspartate aminotransferase (SGOT/AST), alkaline phosphatase, or total levels.
  4. Any grade 2 or higher (as based on the TGS) vital sign or clinical laboratory abnormality not specified in criterion 3 above. Note that any abnormal vital sign may be repeated at the Investigator's discretion.
  5. Participation in research involving product (drug / biologic / device) within 45 days before planned date of first vaccination.
  6. History of a serious reaction to prior influenza vaccination.
  7. History of Guillain-Barré Syndrome (GBS) within 6 weeks following a previous influenza vaccine.
  8. Received any vaccine in the 4 weeks preceding the study vaccination; or any A/H5N1 avian influenza vaccine at any time.
  9. Any known or suspected condition, acquired or congenital, including infection, as determined by history and/or physical examination.
  10. Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the study vaccine. An immunosuppressant dose of will be defined as a systemic dose ≥10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted.
  11. Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the study vaccine or during the study.
  12. Acute disease at the time of enrollment (defined as the presence of a moderate or severe illness with or without fever, or an oral temperature >38.0°C on the planned day of vaccine administration).
  13. Known disturbance of coagulation.
  14. Women who are pregnant or breastfeeding, or plan to become pregnant during the study.
  15. Suspicion or recent history (within one year of planned vaccination) of alcohol or other substance abuse.
  16. Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled or could interfere with evaluation of the vaccine or interpretation of study results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
333 participants (actual)

Study arms

  • Experimental
    Group A

    Biological: Monovalent Avian Influenza VLP (H5N1)

  • Experimental
    Group B

    Biological: Monovalent Avian Influenza VLP (H5N1)

  • Experimental
    Group C

    Biological: Monovalent Avian Influenza VLP (H5N1); Adjuvant

  • Experimental
    Group D

    Biological: Monovalent Avian Influenza VLP (H5N1); Adjuvant

  • Experimental
    Group E

    Biological: Monovalent Avian Influenza VLP (H5N1); Adjuvant

  • Experimental
    Group F

    Biological: Saline Placebo

Interventions

  • BiologicalMonovalent Avian Influenza VLP (H5N1)

    Dose A without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21

  • BiologicalMonovalent Avian Influenza VLP (H5N1)

    Dose B without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21

  • BiologicalMonovalent Avian Influenza VLP (H5N1); Adjuvant

    Dose B with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21

  • BiologicalMonovalent Avian Influenza VLP (H5N1); Adjuvant

    Dose C with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21

  • BiologicalMonovalent Avian Influenza VLP (H5N1); Adjuvant

    Dose D with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21

  • BiologicalSaline Placebo

    Placebo; intramuscular, deltoid, Day 0 and Day 21

06

What researchers measure

Primary outcomes

  1. Number of solicited and unsolicited adverse events in H5N1 VLP antigen dose groups delivering HA with/without Adjuvant 2.

    Time frame: Day 42

Secondary outcomes

  1. Measurement of HAI antibody seroconversion rates and GMT achieved by a constant H5N1 VLP antigen dose alone and in combination with Adjuvant 2.

    Time frame: Day 42

07

Study locations

5 sites
  • Anaheim Clinical Trials
    Anaheim, California 92801, United States
  • Miami Research Associates
    Miami, Florida 33143, United States
  • Broward Research Group
    Pembroke Pines, Florida 33026, United States
  • Johnson County Clin-Trials
    Lenexa, Kansas 66219, United States
  • Clinical Trials of Texas
    San Antonio, Texas 78229, United States
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Aug 2012 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2012
First posted
May 11, 2012
Start
May 2012
Primary completionActual
Aug 2012
CompletionActual
Aug 2013
Last update
Feb 6, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01596725
Lead sponsor
Novavax
Collaborators
Department of Health and Human Services
Responsible party
Sponsor
First posted
May 11, 2012
Start date
May 2012
Primary completion
Aug 2012
Completion
Aug 2013
Last update
Feb 6, 2014

Study contacts

Nigel Thomas, Ph.D
study director · Novavax

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion